Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models

ACY-241 is a novel, orally available and selective histone deacetylase (HDAC) 6 inhibitor in Phase 1b clinical development in multiple myeloma (NCT 02400242). Like the structurally related drug ACY-1215 (ricolinostat), ACY-241 has the potential for a substantially reduced side effect profile versus...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Pengyu, Almeciga-Pinto, Ingrid, Jarpe, Matthew, van Duzer, John H, Mazitschek, Ralph, Yang, Min, Jones, Simon S, Quayle, Steven N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356834/
https://www.ncbi.nlm.nih.gov/pubmed/27926524
http://dx.doi.org/10.18632/oncotarget.13738

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356834/
https://www.ncbi.nlm.nih.gov/pubmed/27926524
http://dx.doi.org/10.18632/oncotarget.13738

Ejemplares similares